Approach to loss of response to advanced therapies in inflammatory bowel disease
N Vootukuru, A Vasudevan - World Journal of …, 2024 - pmc.ncbi.nlm.nih.gov
BACKGROUND Remarkable progress over the last decade has equipped clinicians with
many options in the treatment of inflammatory bowel disease. Clinicians now have the …
many options in the treatment of inflammatory bowel disease. Clinicians now have the …
Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn's disease
J Yao, X Peng, Y Zhong, T Su, A Bihi, J Zhao… - Frontiers in …, 2023 - frontiersin.org
Objectives Ustekinumab (UST) optimization strategies, including shortening intervals and
intravenous reinduction, should be administered to patients with partial or loss of respond …
intravenous reinduction, should be administered to patients with partial or loss of respond …
Long‐term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center
CT Lim, SW Tay, S Elangovan, WC Ong… - Journal of …, 2024 - Wiley Online Library
Abstract Background and Aims Ustekinumab (UST) is an effective biologic for treatment of
inflammatory bowel disease (IBD). However, some patients treated with UST have …
inflammatory bowel disease (IBD). However, some patients treated with UST have …